

Lynda D Roman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5726839/publications.pdf>

Version: 2024-02-01

148
papers

2,316
citations

236612

25
h-index

344852

36
g-index

153
all docs

153
docs citations

153
times ranked

2528
citing authors

#	ARTICLE	IF	CITATIONS
1	Population Distribution of Lifetime Risk of Ovarian Cancer in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 671-676.	1.1	82
2	Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin. <i>Cancer</i> , 2001, 91, 90-100.	2.0	68
3	Effects of imiquimod on vulvar Paget's disease: A systematic review of literature. <i>Gynecologic Oncology</i> , 2015, 139, 165-171.	0.6	59
4	Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity. <i>Gynecologic Oncology</i> , 2021, 160, 586-601.	0.6	56
5	Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2014, 133, 473-479.	0.6	53
6	Time Interval Between Endometrial Biopsy and Surgical Staging for Type I Endometrial Cancer. <i>Obstetrics and Gynecology</i> , 2015, 125, 424-433.	1.2	53
7	Prediction of concurrent endometrial carcinoma in women with endometrial hyperplasia. <i>Gynecologic Oncology</i> , 2015, 139, 261-267.	0.6	51
8	Trends of uterine carcinosarcoma in the United States. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e22.	1.0	47
9	Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma. <i>European Journal of Cancer</i> , 2015, 51, 1978-1988.	1.3	44
10	Significance of abnormal peritoneal cytology on survival of women with stage I-II endometrioid endometrial cancer. <i>Gynecologic Oncology</i> , 2018, 149, 301-309.	0.6	43
11	Impact of depth and extent of lymphovascular space invasion on lymph node metastasis and recurrence patterns in endometrial cancer. <i>Journal of Surgical Oncology</i> , 2015, 112, 669-676.	0.8	42
12	Performance and outcome of pelvic exenteration for gynecologic malignancies: A population-based study. <i>Gynecologic Oncology</i> , 2019, 153, 368-375.	0.6	39
13	Trends and outcomes of women with synchronous endometrial and ovarian cancer. <i>Oncotarget</i> , 2018, 9, 28757-28771.	0.8	38
14	Prognosis of women with stage I endometrioid endometrial cancer and synchronous stage I endometrioid ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 147, 558-564.	0.6	37
15	Minimally Invasive Surgery and Risk of Capsule Rupture for Women With Early-Stage Ovarian Cancer. <i>JAMA Oncology</i> , 2020, 6, 1110.	3.4	37
16	Significance of monocyte counts on tumor characteristics and survival outcome of women with endometrial cancer. <i>Gynecologic Oncology</i> , 2015, 138, 332-338.	0.6	35
17	Association of tumor differentiation grade and survival of women with squamous cell carcinoma of the uterine cervix. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e91.	1.0	34
18	Malignant peritoneal cytology and decreased survival of women with stage I endometrioid endometrial cancer. <i>European Journal of Cancer</i> , 2020, 133, 33-46.	1.3	34

#	ARTICLE	IF	CITATIONS
19	Risk of Subsequent Ovarian Cancer After Ovarian Conservation in Young Women With Stage I Endometrioid Endometrial Cancer. <i>Obstetrics and Gynecology</i> , 2017, 130, 403-410.	1.2	33
20	Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma. <i>Gynecologic Oncology</i> , 2017, 145, 78-87.	0.6	31
21	Ovarian Conservation and Overall Survival in Young Women With Early-Stage Cervical Cancer. <i>Obstetrics and Gynecology</i> , 2017, 129, 139-151.	1.2	31
22	Progestin therapy for obese women with complex atypical hyperplasia: levonorgestrel-releasing intrauterine device vs systemic therapy. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 223, 103.e1-103.e13.	0.7	31
23	Trachelectomy for reproductive-aged women with early-stage cervical cancer: minimally invasive surgery versus laparotomy. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 220, 469.e1-469.e13.	0.7	30
24	Ovarian conservation for young women with early-stage, low-grade endometrial cancer: a 2-step schema. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 224, 574-584.	0.7	30
25	Endometrial cancer arising in adenomyosis versus endometrial cancer coexisting with adenomyosis: are these two different entities?. <i>Archives of Gynecology and Obstetrics</i> , 2017, 295, 1459-1468.	0.8	29
26	The rapid adoption of opportunistic salpingectomy at the time of hysterectomy for benign gynecologic disease in the United States. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 223, 721.e1-721.e18.	0.7	28
27	Role of hysterectomy and lymphadenectomy in the management of early-stage borderline ovarian tumors. <i>Gynecologic Oncology</i> , 2017, 144, 496-502.	0.6	27
28	Adequate pelvic lymphadenectomy and survival of women with early-stage epithelial ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e69.	1.0	27
29	Timing of Intrauterine Manipulator Insertion During Minimally Invasive Surgical Staging and Results of Pelvic Cytology in Endometrial Cancer. <i>Journal of Minimally Invasive Gynecology</i> , 2016, 23, 234-241.	0.3	25
30	Tumor Characteristics and Survival Outcome of Endometrial Cancer Arising in Adenomyosis: An Exploratory Analysis. <i>Annals of Surgical Oncology</i> , 2016, 23, 959-967.	0.7	25
31	Cervical conization of adenocarcinoma in situ: a predicting model of residual disease. <i>American Journal of Obstetrics and Gynecology</i> , 2014, 210, 366.e1-366.e5.	0.7	24
32	Molecular Pathways and Targeted Therapies for Malignant Ovarian Germ Cell Tumors and Sex Cordâ€‘Stromal Tumors: A Contemporary Review. <i>Cancers</i> , 2020, 12, 1398.	1.7	24
33	Paradigm shift from tubal ligation to opportunistic salpingectomy at cesarean delivery in the United States. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 225, 399.e1-399.e32.	0.7	24
34	Molecular Analysis of Mixed Endometrioid and Serous Adenocarcinoma of the Endometrium. <i>PLoS ONE</i> , 2015, 10, e0130909.	1.1	23
35	Nivolumab use for BRCA gene mutation carriers with recurrent epithelial ovarian cancer: A case series. <i>Gynecologic Oncology Reports</i> , 2018, 25, 98-101.	0.3	23
36	Malignant peritoneal cytology and increased mortality risk in stage I non-endometrioid endometrial cancer. <i>Gynecologic Oncology</i> , 2020, 159, 43-51.	0.6	23

#	ARTICLE	IF	CITATIONS
37	Wait-time for hysterectomy and survival of women with early-stage cervical cancer: A clinical implication during the coronavirus pandemic. <i>Gynecologic Oncology</i> , 2020, 158, 37-43.	0.6	23
38	A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube. <i>Gynecologic Oncology</i> , 2014, 132, 517-525.	0.6	22
39	Characteristics and outcomes of reproductive-aged women with early-stage cervical cancer: trachelectomy vs hysterectomy. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 219, 461.e1-461.e18.	0.7	22
40	Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:C. <i>Clinical Immunology</i> , 2015, 161, 197-208.	1.4	21
41	Significance of venous thromboembolism in women with cervical cancer. <i>Gynecologic Oncology</i> , 2016, 142, 405-412.	0.6	20
42	Tumor characteristics and survival outcomes of women with tamoxifen-related uterine carcinosarcoma. <i>Gynecologic Oncology</i> , 2017, 144, 329-335.	0.6	20
43	Possible candidate population for neoadjuvant chemotherapy in women with advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 160, 32-39.	0.6	20
44	Decreasing utilization of minimally invasive hysterectomy for cervical cancer in the United States. <i>Gynecologic Oncology</i> , 2021, 162, 43-49.	0.6	20
45	Risk of metachronous ovarian cancer after ovarian conservation in young women with stage I cervical cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 217, 580.e1-580.e10.	0.7	19
46	A pilot study in using deep learning to predict limited life expectancy in women with recurrent cervical cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 217, 703-705.	0.7	19
47	Assessment of Severe Maternal Morbidity and Mortality in Pregnancies Complicated by Cancer in the US. <i>JAMA Oncology</i> , 2022, 8, 1213.	3.4	18
48	Survival outcome of stage I ovarian clear cell carcinoma with lympho-vascular space invasion. <i>Gynecologic Oncology</i> , 2015, 136, 198-204.	0.6	17
49	Non-prescription cannabis use for symptom management amongst women with gynecologic malignancies. <i>Gynecologic Oncology Reports</i> , 2019, 30, 100497.	0.3	17
50	Escalation of Oncologic Services at the End of Life Among Patients With Gynecologic Cancer at an Urban, Public Hospital. <i>Journal of Oncology Practice</i> , 2015, 11, e163-e169.	2.5	16
51	Recurrence, death, and secondary malignancy after ovarian conservation for young women with early-stage low-grade endometrial cancer. <i>Gynecologic Oncology</i> , 2019, 155, 39-50.	0.6	16
52	Mucinous borderline ovarian tumor versus invasive well-differentiated mucinous ovarian cancer: Difference in characteristics and outcomes. <i>Gynecologic Oncology</i> , 2019, 153, 230-237.	0.6	16
53	Populational trends and outcomes of postoperative radiotherapy for high-risk early-stage cervical cancer with lymph node metastasis: concurrent chemo-radiotherapy versus radiotherapy alone. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 222, 484.e1-484.e15.	0.7	16
54	Hospital surgical volume and perioperative mortality of pelvic exenteration for gynecologic malignancies. <i>Journal of Surgical Oncology</i> , 2020, 121, 402-409.	0.8	16

#	ARTICLE	IF	CITATIONS
55	Survival outcome of women with stage IV uterine carcinosarcoma who received neoadjuvant chemotherapy followed by surgery. <i>Journal of Surgical Oncology</i> , 2018, 117, 488-496.	0.8	15
56	Patterns of utilization and outcome of ovarian conservation for young women with minimal-risk endometrial cancer. <i>Gynecologic Oncology</i> , 2019, 154, 45-52.	0.6	15
57	Utero-ovarian preservation and overall survival of young women with early-stage borderline ovarian tumors. <i>Archives of Gynecology and Obstetrics</i> , 2019, 299, 1651-1658.	0.8	15
58	Vesicoureteral Injury during Benign Hysterectomy: Minimally Invasive Laparoscopic Surgery versus Laparotomy. <i>Journal of Minimally Invasive Gynecology</i> , 2020, 27, 1354-1362.	0.3	15
59	Significance of venous thromboembolism in women with uterine carcinosarcoma. <i>Gynecologic Oncology</i> , 2018, 148, 267-274.	0.6	14
60	Proposal for a Risk-Based Categorization of Uterine Carcinosarcoma. <i>Annals of Surgical Oncology</i> , 2018, 25, 3676-3684.	0.7	14
61	Incorporation of whole pelvic radiation into treatment of stage IVB cervical cancer: A novel treatment strategy. <i>Gynecologic Oncology</i> , 2020, 156, 100-106.	0.6	14
62	Minimally invasive radical hysterectomy for early-stage cervical cancer: Volume-outcome relationship in the early experience period. <i>Gynecologic Oncology</i> , 2020, 158, 390-396.	0.6	14
63	Dysregulation of Placental Functions and Immune Pathways in Complete Hydatidiform Moles. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4999.	1.8	13
64	Route-specific association of progestin therapy and concurrent metformin use in obese women with complex atypical hyperplasia. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1-9.	1.2	13
65	Evolving population-based statistics for rare epithelial ovarian cancers. <i>Gynecologic Oncology</i> , 2020, 157, 3-11.	0.6	13
66	Utilization and perioperative outcome of minimally invasive pelvic exenteration in gynecologic malignancies: A national study in the United States. <i>Gynecologic Oncology</i> , 2021, 161, 39-45.	0.6	13
67	Surgical and oncologic outcomes of hyperthermic intraperitoneal chemotherapy for uterine leiomyosarcoma: A systematic review of literature. <i>Gynecologic Oncology</i> , 2021, 161, 70-77.	0.6	13
68	Endoplasmic reticulum stress in complex atypical hyperplasia as a possible predictor of occult carcinoma and progestin response. <i>Gynecologic Oncology</i> , 2016, 143, 650-654.	0.6	12
69	Characterizing sarcoma dominance pattern in uterine carcinosarcoma: Homologous versus heterologous element. <i>Surgical Oncology</i> , 2018, 27, 433-440.	0.8	12
70	Estrogen Plus Progestin Hormone Therapy and Ovarian Cancer. <i>Epidemiology</i> , 2020, 31, 402-408.	1.2	12
71	Minimally invasive surgery for early-stage ovarian cancer: Association between hospital surgical volume and short-term perioperative outcomes. <i>Gynecologic Oncology</i> , 2020, 158, 59-65.	0.6	12
72	Proposal of an endometrial cancer staging schema with stage-specific incorporation of malignant peritoneal cytology. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 224, 319-321.	0.7	12

#	ARTICLE	IF	CITATIONS
73	Sentinel lymph node biopsy for stage II endometrial cancer: Recent utilization and outcome in the United States. <i>Gynecologic Oncology</i> , 2022, 164, 46-52.	0.6	12
74	Patient compliance for postoperative radiotherapy and survival outcome of women with stage I endometrioid endometrial cancer. <i>Journal of Surgical Oncology</i> , 2017, 116, 482-491.	0.8	11
75	Trachelectomy for stage IB1 cervical cancer with tumor size ≥ 2 cm: trends and characteristics in the United States. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e85.	1.0	11
76	Incidences and risk factors of metachronous vulvar, vaginal, and anal cancers after cervical cancer diagnosis. <i>Gynecologic Oncology</i> , 2018, 150, 501-508.	0.6	11
77	Effectiveness of postoperative chemotherapy for stage IC mucinous ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 154, 505-515.	0.6	11
78	Management of Stage IIB Cervical Cancer: an Overview of the Current Evidence. <i>Current Oncology Reports</i> , 2020, 22, 28.	1.8	11
79	Association between hospital surgical volume and perioperative outcomes of fertility-sparing trachelectomy for cervical cancer: A national study in the United States. <i>Gynecologic Oncology</i> , 2020, 157, 173-180.	0.6	11
80	National trends and outcomes of morbidly obese women who underwent inpatient hysterectomy for benign gynecological disease in the USA. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2021, 100, 459-470.	1.3	11
81	Extent of pelvic lymphadenectomy and use of adjuvant vaginal brachytherapy for early-stage endometrial cancer. <i>Gynecologic Oncology</i> , 2017, 144, 515-523.	0.6	10
82	Implementation of multidisciplinary practice change to improve outcomes for women with placenta accreta spectrum. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 246, 194-196.	0.5	10
83	Association Between Adjuvant Therapy and Survival in Stage II-III Endometrial Cancer: Influence of Malignant Peritoneal Cytology. <i>Annals of Surgical Oncology</i> , 2021, 28, 7591-7603.	0.7	10
84	Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma. <i>Gynecologic Oncology</i> , 2017, 147, 565-571.	0.6	9
85	Recent changes in demographics and outcomes of cervical cancer in the United States. <i>Archives of Gynecology and Obstetrics</i> , 2021, 304, 1-3.	0.8	9
86	Trends in peritoneal cytology evaluation at hysterectomy for endometrial cancer in the United States. <i>Gynecologic Oncology</i> , 2021, 161, 710-719.	0.6	9
87	Single Marital Status and Infectious Mortality in Women With Cervical Cancer in the United States. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1737-1746.	1.2	8
88	Impact of lymphovascular space invasion on tumor characteristics and survival outcome of women with low-grade serous ovarian carcinoma. <i>Journal of Surgical Oncology</i> , 2018, 117, 236-244.	0.8	8
89	Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study. <i>BMC Cancer</i> , 2018, 18, 970.	1.1	8
90	Decreasing secondary primary uterine cancer after breast cancer: A population-based analysis. <i>Gynecologic Oncology</i> , 2019, 154, 169-176.	0.6	8

#	ARTICLE	IF	CITATIONS
91	Treatment and outcome of placenta percreta: Primary cesarean hysterectomy versus conservative management. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 244, 201-203.	0.5	8
92	Diagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study. <i>Gynecologic Oncology</i> , 2020, 157, 21-28.	0.6	8
93	Significance of lymph node ratio on survival of women with borderline ovarian tumors. <i>Archives of Gynecology and Obstetrics</i> , 2020, 301, 1289-1298.	0.8	8
94	Trends in single women with malignancy of the uterine cervix in United States. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e24.	1.0	7
95	Malignant peritoneal cytology in endometrial cancer: Areas of unmet need for evidence. <i>European Journal of Cancer</i> , 2020, 140, 149-150.	1.3	7
96	Utilization and outcomes of adjuvant systemic chemotherapy alone in high risk, early stage cervical cancer in the United States. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 991-1000.	1.2	7
97	Epigenetic resensitization to platinum in recurrent, platinum-resistant ovarian cancer (OC) using guadecitabine (SGI-110), a novel hypomethylating agent (HMA): Results of a randomized phase II study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5547-5547.	0.8	7
98	Epigenetic Dysregulation of Trophoblastic Gene Expression in Gestational Trophoblastic Disease. <i>Biomedicines</i> , 2021, 9, 1935.	1.4	7
99	Characteristics of ovarian tumors of low malignant potential in BRCA mutation carriers: A case series. <i>Gynecologic Oncology Reports</i> , 2015, 13, 36-39.	0.3	6
100	Temporal trends and characteristics of suicide among women with gynecologic malignancy in the United States. <i>Gynecologic Oncology Reports</i> , 2019, 30, 100510.	0.3	6
101	Temporal trends of subsequent breast cancer among women with ovarian cancer: a population-based study. <i>Archives of Gynecology and Obstetrics</i> , 2020, 301, 1235-1245.	0.8	6
102	Significance of Malignant Peritoneal Cytology on Survival of Women with Uterine Sarcoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 1740-1748.	0.7	6
103	Population-level trends and outcomes of sentinel lymph node biopsy in vulvar cancer surgery in the United States. <i>Gynecologic Oncology</i> , 2022, 164, 651-657.	0.6	6
104	Incorporation of sentinel lymph node biopsy in cervical cancer surgery: Recent U.S. trends. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1407-1413.	0.5	6
105	Substantial variability in ovarian conservation at hysterectomy for endometrial hyperplasia. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 227, 255.e1-255.e18.	0.7	6
106	Significance of Lymphovascular Space Invasion by the Sarcomatous Component in Uterine Carcinosarcoma. <i>Annals of Surgical Oncology</i> , 2018, 25, 2756-2766.	0.7	5
107	Efficacy of pegylated liposomal doxorubicin maintenance therapy in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective study. <i>Archives of Gynecology and Obstetrics</i> , 2019, 299, 1641-1649.	0.8	5
108	Survival effect of intra-operative tumor spillage during minimally invasive hysterectomy for early-stage endometrial cancer: a call for research. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 308-309.	1.2	5

#	ARTICLE	IF	CITATIONS
109	Minimally Invasive Surgery and Surgical Volume-Specific Survival and Perioperative Outcome: Unmet Need for Evidence in Gynecologic Malignancy. <i>Journal of Clinical Medicine</i> , 2021, 10, 4787.	1.0	5
110	Intraoperative tumor spill during minimally invasive hysterectomy for endometrial cancer: A survey study on experience and practice. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2021, 267, 256-261.	0.5	5
111	Validation of the 2021 FIGO staging schema for advanced vulvar cancer. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 474-479.	1.2	5
112	Population-level uptake of neoadjuvant chemotherapy for stage IVB endometrial cancer. <i>Gynecologic Oncology</i> , 2022, 165, 428-436.	0.6	5
113	Utilization of sentinel lymph node biopsy in the early ovarian cancer surgery. <i>Archives of Gynecology and Obstetrics</i> , 2023, 307, 525-532.	0.8	5
114	Clinical utility of CA-125 in the management of uterine carcinosarcoma. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e88.	1.0	4
115	Tumor-specific outcome of metachronous uterine malignancy after pelvic irradiation for cervical cancer. <i>Gynecologic Oncology</i> , 2018, 151, 250-256.	0.6	4
116	Association of statins, aspirin, and venous thromboembolism in women with endometrial cancer. <i>Gynecologic Oncology</i> , 2019, 152, 605-611.	0.6	4
117	Cesarean radical hysterectomy for cervical cancer in the United States: a national study of surgical outcomes. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 222, 507-511.e2.	0.7	4
118	Association between definitive chemoradiotherapy wait-time and survival in locally-advanced cervical cancer: Implications during the coronavirus pandemic. <i>Gynecologic Oncology</i> , 2021, 161, 414-421.	0.6	4
119	Secondary haematologic malignancies in women with ovarian cancer receiving poly-ADP ribose polymerase inhibitor therapy. <i>European Journal of Cancer</i> , 2021, 157, 59-62.	1.3	4
120	Minimally invasive interval debulking surgery after neoadjuvant chemotherapy for metastatic ovarian cancer: a national study in the United States. <i>Archives of Gynecology and Obstetrics</i> , 2020, 301, 863-866.	0.8	4
121	A phase Ib/II study of cancer stemness inhibitor napabucasin (BB608) combined with weekly paclitaxel in platinum-resistant ovarian cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 5578-5578.	0.8	4
122	Sentinel lymph node biopsy for vulvar melanoma: trends in tumor stage-specific utilization. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 226, 438-440.	0.7	4
123	Characterizing isolated tumor cells in regional lymph nodes of early endometrial cancer. <i>Gynecologic Oncology</i> , 2022, 165, 264-269.	0.6	4
124	Uptake in sentinel lymph node biopsy for endometrial cancer with T3 classification. <i>Gynecologic Oncology</i> , 2022, 165, 361-368.	0.6	4
125	Prognosis of women with apparent stage I endometrial cancer who had supracervical hysterectomy. <i>Gynecologic Oncology</i> , 2017, 145, 41-49.	0.6	3
126	Fully sialylated alpha-chain of complement 4-binding protein (A2160): a novel prognostic marker for epithelial ovarian carcinoma. <i>Archives of Gynecology and Obstetrics</i> , 2018, 297, 749-756.	0.8	3

#	ARTICLE	IF	CITATIONS
127	Decreasing Trends of Secondary Primary Colorectal Cancer among Women with Uterine Cancer: A Population-Based Analysis. <i>Journal of Clinical Medicine</i> , 2019, 8, 714.	1.0	3
128	Inhibition of poly(ADP-ribose) polymerase induces synthetic lethality in BRIP1 deficient ovarian epithelial cells. <i>Gynecologic Oncology</i> , 2020, 159, 869-876.	0.6	3
129	Association between hysterectomy wait-time and all-cause mortality for micro-invasive cervical cancer: treatment implications during the coronavirus pandemic. <i>Archives of Gynecology and Obstetrics</i> , 2022, 306, 283-287.	0.8	3
130	Risk of Upper-body Adverse Events in Robot-assisted Total Laparoscopic Hysterectomy for Benign Gynecologic Disease. <i>Journal of Minimally Invasive Gynecology</i> , 2021, 28, 1585-1594.e1.	0.3	3
131	Proposal of a simple 2-hand technique at cesarean hysterectomy for placenta accreta spectrum. <i>Archives of Gynecology and Obstetrics</i> , 2022, 305, 1-5.	0.8	3
132	Metastatic extent-specific prognosis of women with stage IVB cervical cancer: multiple versus single distant organ involvement. <i>Archives of Gynecology and Obstetrics</i> , 2023, 307, 533-540.	0.8	3
133	Clinico-pathological significance of suspicious peritoneal cytology in endometrial cancer. <i>Journal of Surgical Oncology</i> , 2021, 124, 687-698.	0.8	2
134	Trends and characteristics of ovarian conservation at hysterectomy for young women with cervical cancer. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2022, 273, 59-64.	0.5	2
135	Validation of a Multivariate Serum Profile for Epithelial Ovarian Cancer Using a Prospective Multi-Site Collection. <i>Nature Precedings</i> , 2010, , .	0.1	1
136	Tumor characteristics and outcome of uterine carcinosarcoma in women aged ≥ 80 years. <i>Surgical Oncology</i> , 2019, 29, 25-32.	0.8	1
137	Adjuvant hysterectomy following primary chemoradiation for stage IB2 and IIA2 cervical cancer: a retrospective comparison of complications for open versus minimally invasive surgery. <i>Radiation Oncology</i> , 2021, 16, 123.	1.2	1
138	Incorporation of vaginal brachytherapy to external beam radiotherapy in adjuvant therapy for high-risk early-stage cervical cancer: A comparative study. <i>Brachytherapy</i> , 2022, 21, 141-150.	0.2	1
139	Hormonal therapy or chemotherapy for early-stage, low-grade endometrial cancer with malignant peritoneal cytology: A comparative effectiveness study. <i>Gynecologic Oncology</i> , 2022, , .	0.6	1
140	Side-to-side reanastomosis after low anterior resection (STELAR): Outcomes, feasibility, and description of procedure performed by a gynecologic oncology service. <i>Journal of Surgical Oncology</i> , 2022, 126, 563-570.	0.8	1
141	Reply. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 218, 264.	0.7	0
142	Financial viewpoint of minimally invasive radical hysterectomy for early cervical cancer: another disadvantage?. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1464-1464.	1.2	0
143	Utility of the 3-tier grouping system for survival discriminatory ability in stage IIA cervical cancer. <i>European Journal of Surgical Oncology</i> , 2021, 47, 331-337.	0.5	0
144	Immunohistochemical analysis of glassy cell carcinoma of the cervix reveals robust lymphocyte infiltrate and the expression of targetable inhibitory immune checkpoints. <i>Archives of Gynecology and Obstetrics</i> , 2021, , 1.	0.8	0

#	ARTICLE	IF	CITATIONS
145	Phase II clinical trial of eribulin in advanced or recurrent cervical cancer (CC).. Journal of Clinical Oncology, 2015, 33, TPS5617-TPS5617.	0.8	0
146	Phase II clinical trial of eribulin (E) in advanced/recurrent cervical cancer.. Journal of Clinical Oncology, 2018, 36, 5526-5526.	0.8	0
147	Proposing the 3â€tier staging system for improving prognostication in Stage I uterine leiomyosarcoma. Journal of Surgical Oncology, 2021, 123, 1099-1108.	0.8	0
148	Population incidence and characteristics of secondary breast cancer after uterine cancer: a competing risk analysis. Archives of Gynecology and Obstetrics, 2022, , 1.	0.8	0